$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2019 Q1 Form 10-K Financial Statement

#000114420419017041 Filed on March 29, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.470M $5.770M $1.330M
YoY Change 10.53% 43.53% 303.03%
% of Gross Profit
Research & Development $3.456M $8.293M -$1.570M
YoY Change 253.74% 748.82% -590.63%
% of Gross Profit
Depreciation & Amortization $44.00K $110.0K $30.00K
YoY Change 76.0% 29.41% 50.0%
% of Gross Profit
Operating Expenses $3.456M $8.293M -$240.0K
YoY Change 253.74% 748.82% -136.92%
Operating Profit -$4.928M -$14.06M
YoY Change 113.61% 181.32%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$100.0K $120.0K $40.00K
YoY Change -1100.0% 140.0% 33.33%
Pretax Income -$5.030M -$3.617M $280.0K
YoY Change 118.7% 42.85% -145.16%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$5.027M -$13.95M $280.0K
YoY Change 118.76% 181.66% -145.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$240.4K -$697.5K $14.93K
COMMON SHARES
Basic Shares Outstanding 29.49M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.230M $7.060M $7.760M
YoY Change 11.05% -9.02% -22.32%
Cash & Equivalents $3.238M $940.0K $2.483M
Short-Term Investments $2.990M $6.120M $5.270M
Other Short-Term Assets $1.230M $1.190M $1.200M
YoY Change 7.89% -0.83% 700.0%
Inventory
Prepaid Expenses $1.103M $1.103M
Receivables $800.0K $1.920M $670.0K
Other Receivables $0.00 $90.00K $0.00
Total Short-Term Assets $8.257M $10.27M $9.623M
YoY Change 4.92% 6.76% -7.83%
LONG-TERM ASSETS
Property, Plant & Equipment $611.0K $650.0K $392.0K
YoY Change 49.02% 66.67% 31.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.594M $310.0K $1.800M
YoY Change 215.26% -78.01% 459.01%
Total Long-Term Assets $3.594M $960.0K $1.800M
YoY Change 133.38% -46.67% 445.45%
TOTAL ASSETS
Total Short-Term Assets $8.257M $10.27M $9.623M
Total Long-Term Assets $3.594M $960.0K $1.800M
Total Assets $11.85M $11.23M $11.42M
YoY Change 25.94% -1.66% 6.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.029M $4.550M $1.424M
YoY Change 54.26% 220.42% 312.75%
Accrued Expenses $2.246M $1.040M $817.0K
YoY Change 410.45% 26.83% 444.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.480M $6.210M $5.543M
YoY Change 51.97% 12.09% 544.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.050M
YoY Change
Total Long-Term Liabilities $3.045M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.480M $6.210M $5.543M
Total Long-Term Liabilities $3.045M $0.00 $0.00
Total Liabilities $11.53M $6.210M $5.543M
YoY Change 106.58% 12.09% 541.55%
SHAREHOLDERS EQUITY
Retained Earnings -$99.05M -$80.08M
YoY Change 6.59%
Common Stock $98.34M $85.96M
YoY Change 1.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $326.0K $5.020M $5.880M
YoY Change
Total Liabilities & Shareholders Equity $11.85M $11.23M $11.42M
YoY Change 25.94% -1.66% 6.1%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$5.027M -$13.95M $280.0K
YoY Change 118.76% 181.66% -145.16%
Depreciation, Depletion And Amortization $44.00K $110.0K $30.00K
YoY Change 76.0% 29.41% 50.0%
Cash From Operating Activities -$835.0K -$12.39M -$2.930M
YoY Change -60.72% 424.03% 144.17%
INVESTING ACTIVITIES
Capital Expenditures $4.000K $369.0K -$60.00K
YoY Change -91.11% 105.0%
Acquisitions
YoY Change
Other Investing Activities $3.140M -$850.0K $2.810M
YoY Change 7.9% -120.38% 255.7%
Cash From Investing Activities $3.131M -$1.218M $2.750M
YoY Change 9.32% -130.56% 248.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $59.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 12.07M 200.0K
YoY Change -100.0% 3742.36%
NET CHANGE
Cash From Operating Activities -835.0K -12.39M -2.930M
Cash From Investing Activities 3.131M -1.218M 2.750M
Cash From Financing Activities 0.000 12.07M 200.0K
Net Change In Cash 2.296M -1.541M 20.00K
YoY Change 200.92% -179.6% -104.88%
FREE CASH FLOW
Cash From Operating Activities -$835.0K -$12.39M -$2.930M
Capital Expenditures $4.000K $369.0K -$60.00K
Free Cash Flow -$839.0K -$12.76M -$2.870M
YoY Change -61.35% 401.45% 139.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1195000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2483000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
6122000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
5273000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1197000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
10270000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
9623000
CY2018Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
307000
CY2017Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1408000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
958000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1800000
CY2018Q4 us-gaap Assets
Assets
11228000
CY2017Q4 us-gaap Assets
Assets
11423000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4548000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1424000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1042000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
817000
CY2018Q4 bcli Deferred Grant Income
DeferredGrantIncome
0
CY2017Q4 bcli Deferred Grant Income
DeferredGrantIncome
2625000
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
622000
CY2017Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
677000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6212000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5543000
CY2018Q4 us-gaap Liabilities
Liabilities
6212000
CY2017Q4 us-gaap Liabilities
Liabilities
5543000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94620000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
85944000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94023000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80075000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11228000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11423000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div><table style="border: none; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%; table-layout: fixed;"><tr><td style="border-width: initial; border-style: none; border-color: initial; padding: 0px; vertical-align: top; width: 0.85in;"></td><td style="border-width: initial; border-style: none; border-color: initial; padding: 0pt 0px; vertical-align: top; width: 0.5in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">B.</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: top;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; text-align: justify; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates:</div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.25in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 1.35in; margin-top: 0px; text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20757816
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18976169
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20757816
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18976169
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.0833
CY2018 bcli Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2018 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2018 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2017Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
98000
CY2018Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2009000
CY2017Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
672000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1103000
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
276000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2220000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1853000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1569000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8293000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
977000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5770000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4022000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-14063000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-4999000
CY2018 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-115000
CY2017 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-47000
CY2018 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.70
CY2017 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.26
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18777348
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4578867
CY2018 us-gaap Depreciation
Depreciation
110000
CY2017 us-gaap Depreciation
Depreciation
85000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1461000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
651000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
392000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
212000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
43000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
255000
CY2018 bcli Amounts Of Grants Received
AmountsOfGrantsReceived
2009000
CY2018 bcli Grants Underlying Basis
GrantsUnderlyingBasis
The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
CY2018 bcli Lease Agreement Termination Description
LeaseAgreementTerminationDescription
option to terminate the agreement with 4 month pre-notice, before December 31, 2019
CY2018 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P8M
CY2017 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P8M
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
9902000
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
57768000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
51107000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15916000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14090000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15916000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14090000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
554000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
209000
CY2017 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
105000
CY2017 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
62000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5880000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
917000
CY2018 bcli Research And Development Cost
ResearchAndDevelopmentCost
16330000
CY2017 bcli Research And Development Cost
ResearchAndDevelopmentCost
6795000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1496287
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
940954
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M25D
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13948000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
314000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M2D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
840579
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
811824
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1019000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
616000
CY2007Q3 bcli Warrants Issued To Purchase Of Common Stock
WarrantsIssuedToPurchaseOfCommonStock
672222
CY2007Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3
CY2014Q2 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
5.22
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2080755
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q4 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
4408000
CY2017Q4 bcli Receipts On Account Of Shares
ReceiptsOnAccountOfShares
0
CY2018 bcli Stock Issued During Periodvalueexercise And Reissuance Of Warrants
StockIssuedDuringPeriodvalueexerciseAndReissuanceOfWarrants
12040000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-4952000
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
102000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
62000
CY2018 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
917000
CY2017 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
554000
CY2018 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
238000
CY2017 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
2792000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3124000
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1079000
CY2018 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
-2625000
CY2017 bcli Increase Decrease In Deferred Grant Income
IncreaseDecreaseInDeferredGrantIncome
2625000
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
170000
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
975000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12388000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2364000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
369000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
180000
CY2018 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
849000
CY2017 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-4170000
CY2018 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
0
CY2017 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
4000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1218000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3986000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12065000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
314000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1541000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1936000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
547000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12040000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3617000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-2532000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10331000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2420000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13948000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4952000
CY2018Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12040000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19997710
CY2018 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
102000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2018Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
90000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59000000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q3 us-gaap Grants Receivable
GrantsReceivable
15912000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
71031012
CY2018 dei Trading Symbol
TradingSymbol
BCLI
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29490610
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-017041-index-headers.html Edgar Link pending
0001144204-19-017041-index.html Edgar Link pending
0001144204-19-017041.txt Edgar Link pending
0001144204-19-017041-xbrl.zip Edgar Link pending
bcli-20181231.xml Edgar Link completed
bcli-20181231.xsd Edgar Link pending
bcli-20181231_cal.xml Edgar Link unprocessable
bcli-20181231_def.xml Edgar Link unprocessable
bcli-20181231_lab.xml Edgar Link unprocessable
bcli-20181231_pre.xml Edgar Link unprocessable
ex10-52_001.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv512716_10k.htm Edgar Link pending
tv512716_ex10-52.htm Edgar Link pending
tv512716_ex21.htm Edgar Link pending
tv512716_ex23-1.htm Edgar Link pending
tv512716_ex31-1.htm Edgar Link pending
tv512716_ex31-2.htm Edgar Link pending
tv512716_ex32-1.htm Edgar Link pending
tv512716_ex32-2.htm Edgar Link pending